JP2019522037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522037A5 JP2019522037A5 JP2019504916A JP2019504916A JP2019522037A5 JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5 JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- hour
- vivo
- cell
- adjusted according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078313A JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368707P | 2016-07-29 | 2016-07-29 | |
| US62/368,707 | 2016-07-29 | ||
| US201662417572P | 2016-11-04 | 2016-11-04 | |
| US62/417,572 | 2016-11-04 | ||
| US201662422504P | 2016-11-15 | 2016-11-15 | |
| US62/422,504 | 2016-11-15 | ||
| US201662426107P | 2016-11-23 | 2016-11-23 | |
| US62/426,107 | 2016-11-23 | ||
| US201762503238P | 2017-05-08 | 2017-05-08 | |
| US62/503,238 | 2017-05-08 | ||
| US201762534067P | 2017-07-18 | 2017-07-18 | |
| US62/534,067 | 2017-07-18 | ||
| PCT/US2017/043979 WO2018022771A1 (en) | 2016-07-29 | 2017-07-26 | Uses of indolinone compounds |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020204766A Division JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Division JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522037A JP2019522037A (ja) | 2019-08-08 |
| JP2019522037A5 true JP2019522037A5 (enExample) | 2019-10-17 |
| JP6885629B2 JP6885629B2 (ja) | 2021-06-16 |
Family
ID=61011754
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504916A Active JP6885629B2 (ja) | 2016-07-29 | 2017-07-26 | インドリノン化合物の使用 |
| JP2020204766A Active JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Active JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020204766A Active JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Active JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10159660B2 (enExample) |
| EP (1) | EP3490553B1 (enExample) |
| JP (3) | JP6885629B2 (enExample) |
| KR (2) | KR20210095721A (enExample) |
| CN (2) | CN114569606B (enExample) |
| CA (1) | CA3029851A1 (enExample) |
| MX (1) | MX395539B (enExample) |
| PH (1) | PH12019500070A1 (enExample) |
| SG (1) | SG11201811661TA (enExample) |
| TW (2) | TWI780061B (enExample) |
| WO (1) | WO2018022771A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111777596A (zh) * | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| KR102375929B1 (ko) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
| US10159660B2 (en) * | 2016-07-29 | 2018-12-25 | Oncternal Therapeutics, Inc. | Uses of indolinone compounds |
| CN110818611B (zh) * | 2018-08-13 | 2023-01-24 | 中国科学院上海药物研究所 | 一类吲哚酮类化合物、其制备方法、药物组合物和用途 |
| CN113365622A (zh) * | 2018-11-30 | 2021-09-07 | 艾普托斯生物科学公司 | 使用2，3-二氢异吲哚-1-酮化合物的组合疗法及用于治疗具有各种突变的患者的方法 |
| WO2022060856A2 (en) * | 2020-09-17 | 2022-03-24 | Oklahoma Medical Research Foundation | Inhibition of endothelial ets family transcription factors promotes flow-dependent ocular vessel regression |
| WO2022266491A1 (en) * | 2021-06-18 | 2022-12-22 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof |
| TW202320802A (zh) | 2021-07-16 | 2023-06-01 | 美商塞萊托藥品股份有限公司 | Ｂｃｌ抑制劑之脂質體調配物 |
| WO2025137592A2 (en) * | 2023-12-21 | 2025-06-26 | Anuj Bellare | Diazirine monomers and polymer compositions derived therefrom |
| WO2025235561A1 (en) * | 2024-05-08 | 2025-11-13 | Enspire Group LLC | Venetoclax oral drugs and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288436C (en) | 1983-07-22 | 1991-09-03 | David Paul Hesson | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| WO2000033834A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| AU2001241798A1 (en) | 2000-02-28 | 2001-09-12 | Sugen, Inc. | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| CA2562151C (en) | 2004-04-30 | 2016-09-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| EP2687206B1 (en) | 2006-12-29 | 2017-12-13 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| AU2008242488B2 (en) | 2007-04-20 | 2014-10-30 | The Research Foundation For The State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
| US8377992B2 (en) | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| US20110218155A1 (en) | 2008-10-10 | 2011-09-08 | Dana-Farber Cancer Institute, Inc. | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
| WO2010083505A1 (en) | 2009-01-19 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| CN102516152B (zh) | 2011-12-12 | 2014-12-10 | 华东师范大学 | 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用 |
| TW201346030A (zh) | 2012-04-02 | 2013-11-16 | Gradalis Inc | 依汶氏（ＥＷＩＮＧ’Ｓ）肉瘤雙功能ｓｈＲＮＡ設計 |
| AU2013245812B2 (en) | 2012-04-12 | 2017-04-06 | Georgetown University | Methods and compositions for treating Ewing's sarcoma family of tumors |
| MX2015000804A (es) * | 2012-07-20 | 2016-03-11 | Star Biotechnology Llc | Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1. |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| AU2014251028A1 (en) * | 2013-04-08 | 2015-11-05 | Janssen Pharmaceutica Nv | Ibrutinib combination therapy |
| WO2014173241A1 (en) * | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| KR101500363B1 (ko) * | 2013-07-01 | 2015-03-16 | 현대자동차 주식회사 | 하이브리드 자동차의 동력전달장치 |
| KR20160037201A (ko) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| RU2016114498A (ru) | 2013-10-24 | 2017-11-29 | Джорджтаун Юниверсити | Способы и композиции для лечения раковых заболеваний |
| TWI617309B (zh) * | 2013-10-25 | 2018-03-11 | 製藥公司 | 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法 |
| CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| US9260415B2 (en) * | 2013-12-05 | 2016-02-16 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| EP3131552B1 (en) * | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
| WO2016014859A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| WO2016030509A1 (en) * | 2014-08-28 | 2016-03-03 | Oncoethix Gmbh | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
| CN111777596A (zh) | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| KR102375929B1 (ko) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
| US10159660B2 (en) | 2016-07-29 | 2018-12-25 | Oncternal Therapeutics, Inc. | Uses of indolinone compounds |
| US20190255127A1 (en) | 2018-02-21 | 2019-08-22 | Batu Biologics, Inc. | Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells |
-
2017
- 2017-07-26 US US15/660,566 patent/US10159660B2/en active Active
- 2017-07-26 CN CN202210216619.0A patent/CN114569606B/zh active Active
- 2017-07-26 KR KR1020217023307A patent/KR20210095721A/ko not_active Ceased
- 2017-07-26 CA CA3029851A patent/CA3029851A1/en active Pending
- 2017-07-26 CN CN201780059006.8A patent/CN109789127B/zh active Active
- 2017-07-26 WO PCT/US2017/043979 patent/WO2018022771A1/en not_active Ceased
- 2017-07-26 JP JP2019504916A patent/JP6885629B2/ja active Active
- 2017-07-26 SG SG11201811661TA patent/SG11201811661TA/en unknown
- 2017-07-26 MX MX2019000867A patent/MX395539B/es unknown
- 2017-07-26 KR KR1020197005697A patent/KR102282794B1/ko active Active
- 2017-07-26 EP EP17835216.7A patent/EP3490553B1/en active Active
- 2017-07-28 TW TW106125399A patent/TWI780061B/zh active
- 2017-07-28 TW TW111135922A patent/TWI857351B/zh active
-
2018
- 2018-08-27 US US16/114,076 patent/US10646470B2/en active Active
-
2019
- 2019-01-10 PH PH12019500070A patent/PH12019500070A1/en unknown
-
2020
- 2020-04-13 US US16/847,516 patent/US11285132B2/en active Active
- 2020-12-10 JP JP2020204766A patent/JP7182304B2/ja active Active
-
2021
- 2021-05-06 JP JP2021078313A patent/JP7208659B2/ja active Active
-
2022
- 2022-03-28 US US17/705,746 patent/US12161626B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Janiszewski et al. | Content and process priming: A review | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2024010140A (es) | Nuevos metodos. | |
| JP2015057451A5 (enExample) | ||
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| PH12018501903B1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| WO2015121348A3 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor | |
| EP4545143A3 (en) | Early intervention methods to prevent or ameliorate toxicity | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| MX2016006318A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| JP2019532634A5 (enExample) | ||
| TN2016000083A1 (en) | Methods and tools relating to the administration of contrast medium | |
| PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| JP2017061488A5 (enExample) | ||
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| NZ712584A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
| JP2019518052A5 (enExample) | ||
| ME02839B (me) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt | |
| UA117105U (uk) | Спосіб застосування препарату xyla для анестезії плідників осетрових в процесі штучного відтворення | |
| HK1214511A1 (zh) | 盐酸兰地洛尔在快速性心律失常的长期治疗中的用途 | |
| HK1224578A1 (en) | Drug mixing and delivery system and method |